ABDA-Artikelstamm: German Article Master Data Explained

The ABDA-Artikelstamm is the German pharmaceutical article master file: one record per PZN, carrying the commercial and legal facts about every medicine and pharmacy-typical product on the German market, published twice a month on the 1st and the 15th by ABDATA Pharma-Daten-Service. It is the file that tells a pharmacy system what a pack costs, whether it may be dispensed, whether it is reimbursable, and whether a discount contract applies. Nearly every price shown on a German pharmacy screen traces back to it.

This article is about the commercial layer. The clinical layer, meaning interactions, patient-individual risk checks and active ingredient dossiers, sits in the separate ABDA database product family. If your question is about therapy or safety, you are in the wrong file. If your question is about price, dispensing status, reimbursement or logistics, the Artikelstamm is the authoritative German answer.

What "article master data" means, and why it is not product data

An article is a specific sellable pack, not a product. That distinction is the single most important thing to understand about the Artikelstamm, and it is where most integration projects go wrong.

Consider one medicine. It exists in three strengths, each in three pack sizes, each supplied by the original manufacturer plus several parallel importers. That is one product in the clinical sense and dozens of articles in the commercial sense. Each of those articles has its own PZN, its own price, potentially its own availability status and its own reimbursement treatment.

Article-level granularity is not bureaucratic overhead. It is a requirement of German pharmaceutical law and reimbursement practice:

• Pricing is per pack. The statutory margins under the Arzneimittelpreisverordnung are calculated per pack, not per molecule.
• Discount contracts are per article. A health insurer's rebate contract under section 130a SGB V binds a specific supplier's specific pack, not the active ingredient.
• Substitution rules operate on packs. Deciding which alternative may be dispensed requires comparing strength, pack size and dosage form at the article level.
• Logistics is per pack. Ordering, stock and returns run on the PZN, never on the product name.

What an ABDA-Artikelstamm record contains

ABDATA groups the Artikelstamm content into base data, legal information, pricing, substitution and distribution information. In practice a record answers the following.

Two extensions exist for specific needs. Artikelstamm Plus V adds supply contract information beyond the standard framework agreements, including medical device supply contracts. Artikelstamm Plus H3 supports the calculation of billing prices for compounded parenteral preparations under the Hilfstaxe, which is the specialist case that hospital-supplying and compounding pharmacies cannot do without.

The twice-monthly cycle, and why the date matters

The ABDA-Artikelstamm is published on the 1st and the 15th of each month. That cadence is not a convention chosen by ABDATA; it mirrors the publication rhythm of the IFA information services, which is where the supplier-reported article data originates.

The consequences are structural rather than cosmetic.

• Prices change in steps, not continuously. A price agreed with a supplier today becomes effective in the market on the next publication date, provided the reporting deadline was met.
• There is a blind window. Between two deliveries, a system holds a snapshot. If a pack is discontinued on the 3rd, the local data will not know until the 15th unless a separate live source is consulted.
• The load has to succeed, every time. An update that fails over a weekend means Monday morning trading on stale prices, with the resulting billing corrections landing weeks later.

"Our main problem is outdated PZNs and records in our system, which lead to errors." Specialist pharmaceutical distributor (translated from German)

How the data originates: from IFA to the Artikelstamm

The Artikelstamm is not written by ABDATA from scratch. It is built on data that suppliers themselves report.

1. A supplier, meaning any company placing a medicine or pharmacy-typical product on the German market, reports the article to IFA GmbH, the Informationsstelle für Arzneispezialitäten.
2. IFA assigns a PZN, the eight-digit identifier that has been the German national product code since 2013 and is anchored in section 131 SGB V as the uniform national identifier.
3. IFA publishes the article and its commercial attributes on the 1st and the 15th.
4. ABDATA takes that data, verifies it, and supplements it with the legal, reimbursement and substitution logic that turns raw supplier reports into a usable article master file.
5. Software vendors, wholesalers, pharmacies and hospitals load the resulting Artikelstamm into their systems.

The important implication: the quality ceiling of the Artikelstamm is set by the supplier's own reporting discipline. ABDATA can verify and enrich, but it cannot know about a price change that was never reported, or reported late.

Which systems consume the Artikelstamm

What changed recently: ALBVVG, section 130e and inflation adjustment

The legacy content on this topic predates three regulatory changes that reshaped what the pricing fields in the Artikelstamm actually mean. Anyone reading German price data without knowing about them will misread it.

ALBVVG (2023)

The Arzneimittel-Lieferengpassbekämpfungs- und Versorgungsverbesserungsgesetz, the Act to Combat Drug Shortages and Improve Supply, entered into force on 26 July 2023. It was a direct response to the paediatric medicine shortages of the previous winter, and it had concrete price effects:

• Fixed reimbursement amounts removed for paediatric medicines. Effective 1 February 2024, fixed amounts were lifted for 472 finished medicinal products across 41 fixed amount groups, following a decision of 20 November 2023.
• A 50 percent headroom on the frozen price base. For those listed paediatric medicines without a fixed amount, the previous price base was raised by 50 percent, so a manufacturer can raise the selling price up to that new base without incurring the price moratorium rebate.
• Higher wholesale fixed surcharge. The fixed per-pack surcharge for prescription-only medicines under the Arzneimittelpreisverordnung rose from 70 cents to 73 cents.

Each of these is visible in the Artikelstamm as a changed number with no explanatory field attached. A price jump on a paediatric antibiotic in 2024 is not a manufacturer acting opportunistically; it is legislation working as intended.

Kombinationsabschlag under section 130e SGB V

The combination discount is the newest of the statutory manufacturer rebates and the one most often missing from older explainers. Under section 130e SGB V, health insurers receive a discount of 20 percent of the manufacturer's selling price excluding VAT for medicines with new active ingredients used in a combination designated by the Federal Joint Committee, for products supplied at the expense of the statutory insurers from 2 May 2023 onwards.

The discount lapses prospectively once the Federal Joint Committee has determined that the combination offers at least considerable added benefit, or is expected to. ALBVVG amended the provision to task the National Association of Statutory Health Insurance Funds with regulating the implementation details.

For anyone modelling the actual cost to a payer, this is decisive: the list price of a combination therapy component can be materially higher than what the insurer effectively pays.

Price moratorium and inflation adjustment

The section 130a paragraph 3a SGB V price moratorium freezes manufacturer prices at the level of 1 August 2009. Increases above that frozen base trigger a rebate to the insurers equal to the increase, which in effect neutralises them.

The moratorium is not absolute. Since 1 July 2018, and on 1 July of every year since, the frozen price base is raised by the change in the consumer price index for Germany as published by the Federal Statistical Office. This is the inflation adjustment, and it is the one legitimate route to a higher effective price without a rebate. The moratorium as currently legislated runs to 31 December 2026.

The recurring failure modes in Artikelstamm projects

• Treating the PZN as permanent. PZNs are retired when articles leave the market. A list of PZNs maintained in a spreadsheet over years silently accumulates records that no longer resolve.
• Confusing list price with effective price. Statutory rebates, discount contracts and the combination discount all sit between the published price and what a payer actually pays.
• Ignoring the delta. Loading a full file every cycle without tracking what changed means nobody notices the price change that mattered until a billing correction arrives.
• Assuming German scope is enough. Import, parallel trade and shortage substitution all require the ability to compare a German pack against packs in other countries, which article data alone does not provide.

Where pharmazie.com fits

We license the ABDA-Artikelstamm and integrate it alongside more than 25 databases covering over 50 countries, with 50,000+ German products and 120,000+ international products searchable together. That means a single query resolves a PZN into its German commercial record, its clinical profile, its shortage status and its international equivalents, instead of requiring four separate lookups in four separate tools. For cross-layer and cross-border questions across DACH and 50+ countries, that consolidated view is the most complete single answer available.

Access is through a web platform and a REST API that integrates with ERP, inventory management and MSV3 order processing, so a team without a data engineering function can still work with article-level German data. DACON has been building this infrastructure since 1989.

This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.